The Global Health Body Sounds Concern Over Severe Shortage of Obesity Injections
Under one in 10 people eligible to benefit from obesity jabs such as Wegovy are able to get them, states the WHO as it issues its initial advice on the drugs.
Given in excess of 1,000,000,000 people worldwide now obese, it is advocating for increased and just access to GLP-1 medication.
According to projections, over two billion are projected to be living with obesity by 2030 if no action is taken.
"The latest guidelines recognises that obesity is a long-term condition that can be treated with comprehensive and continuous support," said WHO director-general Tedros Adhanom Ghebreyesus.
High costs, constrained manufacturing, and logistical bottlenecks are major obstacles to widespread access to the jabs that can aid individuals in losing substantial body mass, says the body.
Weight-Loss Drug Supply Crisis
Even in the current most optimistic case, the manufacturing of these medications would only suffice for about 100 million people β under 10% of the global need, per the WHO.
The advice calls on countries and companies to widen access, via approaches like voluntary licensing.
The intellectual property rights on a key compound β the core component of a leading brand β is set to lapse in multiple nations in 2026.
How Obesity Injections Work
These medications mimick a body's own hormone to reduce digestion speed, reduce hunger and boost satiety so users reduce food intake.
Individuals commonly start to lose weight after several weeks of beginning the weekly injections.
Evidence indicates people may see weight return within a year of discontinuing the medication, because their normal food cravings return.
Being above a healthy weight raises your chance for experiencing medical conditions, such as type 2 diabetes, cardiovascular issues, stroke, and some malignancies.
Excess weight concerns people in all nations and was linked to 3.7 million fatalities worldwide in 2024, as per the WHO.
